Acumen Pharmaceuticals, Inc.
ABOS
$2.72
$0.041.49%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 32.34% | 11.13% | -99.40% | -93.61% | -125.22% |
| Total Depreciation and Amortization | 2.27% | 4.44% | 4.44% | 2.27% | 12.82% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 79.39% | 111.58% | 1,436.26% | 92.09% | -19.90% |
| Change in Net Operating Assets | -63.58% | -288.16% | 66.67% | -81.02% | 35.79% |
| Cash from Operations | 29.83% | -23.96% | -92.40% | -91.06% | -227.34% |
| Capital Expenditure | -- | -- | -80.00% | -618.18% | 100.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -11.51% | 499.83% | 2.09% | 412.97% | 160.79% |
| Cash from Investing | -11.51% | 499.83% | 2.08% | 411.74% | 160.78% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -99.53% | -- |
| Repurchase of Common Stock | 100.00% | -- | -- | -128.13% | 97.69% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | 100.00% |
| Cash from Financing | 122.22% | 100.00% | 100.00% | -100.51% | -100.03% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 193.40% | 128.82% | -68.37% | 72.60% | 108.71% |